News
-
-
Sir David Weatherall, an ‘iconic’ scientist who carried out groundbreaking work in thalassaemia, dies
The international scientific and research community is mourning the loss of Sir David Weatherall, the highly-regarded British clinical scientist and haematologist whose studies focused on haemoglobin disorders and thalassaemia. His…
Read More » -
WHO Award granted to the Thalassaemia International Federation
Important Announcement ONE OF THE MOST PRESTIGIOUS HONOURS OF THE WORLD HEALTH ORGANIZATION (WHO) HAS BEEN GRANTED TO THE THALASSAEMIA INTERNATIONAL FEDERATION (TIF)! We are extremely proud to announce that…
Read More » -
TIF guides Egypt and pioneers in the treatment of thalassaemia all over the world!
Press Release Thalassaemia International Federation (TIF), based in Cyprus guides Egypt and pioneers in the treatment of thalassaemia all over the world! TIF meets with the Egyptian Minister of Health…
Read More » -
CLINICAL ALERT: New study highlights ‘unsafe’ T2* MRI method being used for iron overload assessment in thousands of patients
New study highlights ‘unsafe’ T2* MRI method being used for iron overload assessment in thousands of patients. TIF became aware of the results from a new study, to be presented…
Read More » -
POLICY NEWS | TIF Issues Statement On The New EU Regulation For Blood, Tissues And Cells
This single Regulation, once approved by Member States, will replace all existing EU Directives on Blood, Tissues and Cells and will be equally applicable in the EU territory. The proposal…
Read More » -
Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?
In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…
Read More » -
Coming Up This Thursday: Discussion On Access To Innovative Therapies – The Reblozyl Case
After receiving numerous questions from patients regarding the innovative treatment for β-thalassaemia Reblozyl (luspatercept), approved for use in the US, Europe, and Canada, TIF proceeds to organise an interactive, online…
Read More » -
UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease
For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK National Health Service (NHS). Crizanlizumab (Adakveo) by Novartis…
Read More » -
BLOOD TRANSFUSION | Hemanext Begins Rollout of Hemanext ONE® RBC Processing And Storage System In Europe
Physicians in Norway have initiated recruitment of chronically transfused patients with haematological malignancies, including myelodysplastic syndrome (MDS), to receive transfusions using RBCs processed and stored with the Hemanext ONE® system.…
Read More »